Cell News and Research

RSS

TSI organizes clinical, research and educational programs

The Wake Forest University Translational Science Institute (TSI) has announced a number of organizational changes. Four programs and four specialized centers have been organized to function collaboratively in support of research conducted at Wake Forest University Baptist Medical Center.

18 Dec 2009

Umbilical cord stem cells may be useful in treating blood disorders

Stem cells that could one day provide therapeutic options for muscle and bone disorders can be easily harvested from the tissue of the umbilical cord, just as the blood that goes through it provides precursor cells to treat some blood disorders, said University of Pittsburgh School of Medicine researchers in the online version of the Journal of Biomedicine and Biotechnology.

18 Dec 2009

New technology sheds light on intracellular transport

Using new technology developed in his University of Oregon lab, chemist Andrew H. Marcus and his doctoral student Eric N. Senning have captured what they describe as well-orchestrated, actin-driven, mitochondrial movement within a single cell.

18 Dec 2009

JDRF to work with Johnson & Johnson to develop drug targets and pathways for treating diabetes

The Juvenile Diabetes Research Foundation, a leader in setting the agenda for diabetes research worldwide, said today that it will begin working with The Johnson & Johnson Corporate Office of Science and Technology, and its affiliates, to speed the development of drug targets and pathways to promote the survival and function of insulin-producing cells in people who have diabetes.

18 Dec 2009

Ambit Biosciences and Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors

Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that they have entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications.

18 Dec 2009

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

Researchers have developed a novel animal model showing that four commonly used chemotherapy drugs disrupt the birth of new brain cells, and that the condition could be partially reversed with the growth factor IGF-1.

18 Dec 2009

Flu-fighting proteins found in human cells stop flu virus, uncover scientists

In findings that may lead to better ways to prevent and treat influenza and other viral infections, researchers report the discovery of a family of naturally occurring antiviral agents in human cells.

18 Dec 2009

Regulus Therapeutics wins exclusive rights to modulate microRNAs

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., announced today that it has obtained exclusive rights from the California Institute of Technology to inventions made in the laboratory of David Baltimore, Ph.D. covering methods and compositions for modulating microRNA-146 and microRNA-155.

18 Dec 2009

Roche Diagnostics and Takara Bio enter into license agreement

Roche Diagnostics and Takara Bio, the Shiga (Japan)-based supplier of systems for use in life science research, announced that they have entered into a license agreement for use of the melting curve analysis technology and SYBR Green techniques in their Kits and Instruments for Real Time PCR.

From Roche Sequencing and Life Science 18 Dec 2009

Comprehensive approaches to understand the interaction of H1N1 strains with human cells

Scientists have generated hundreds of new leads in the fight against the H1N1 flu pandemic, according to two new studies published online December 17th in the journal Cell, a Cell Press publication.

18 Dec 2009

Phase 2 clinical study of STA-9090 in NSCLC initiated

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 2 clinical study of STA-9090 in non-small cell lung cancer (NSCLC).

18 Dec 2009

ARIAD Pharmaceuticals completes enrollment of patients for Phase 3 clinical trial of ridaforolimus

ARIAD Pharmaceuticals, Inc. today announced the completion of patient enrollment in its pivotal, Phase 3 clinical trial of oral ridaforolimus, its investigational mTOR inhibitor, in patients with metastatic soft-tissue and bone sarcomas.

18 Dec 2009

Calorie-intake restriction can benefit longevity and help prevent cancer

Researchers from the University of Alabama at Birmingham (UAB) have discovered that restricting consumption of glucose, the most common dietary sugar, can extend the life of healthy human-lung cells and speed the death of precancerous human-lung cells, reducing cancer's spread and growth rate.

18 Dec 2009

Ligand Pharmaceuticals, Neurogen revise merger agreement

Ligand Pharmaceuticals Incorporated and Neurogen Corporation announced today they have amended their merger agreement to increase the merger consideration payable

18 Dec 2009

Scientists discover new model to asses homeostatic relationships between body substances

The Center for Modeling Optimal Outcomes, LLC, a New Jersey based think tank focused on the application of neuroscience in business, inadvertently discovered a scientifically verifiable model for assessing homeostasis (balance) between substances in the body.

18 Dec 2009

La Jolla Institute for Allergy & Immunology awarded $18.8M NIH grant for infectious diseases study

Researchers from the La Jolla Institute for Allergy & Immunology will take aim at several of the world's most dangerous infectious diseases - tuberculosis, malaria and dengue virus -- in a five-year, $18.8 million federally-funded set of projects seeking to make new inroads toward vaccines against the disorders.

17 Dec 2009

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).

17 Dec 2009

Promising breakthrough in adjuvant development may lead to cost-effective therapeutic vaccines

It should be possible to use therapeutic vaccines to create both cheap and effective drugs for diseases like cancer and allergies. One problem in developing such vaccines has previously been the lack of adjuvants, substances that make vaccines more effective. However, there has now been a major breakthrough in this area. The study, led by Swedish scientists at Uppsala University, is published in the December issue of the journal Vaccine.

17 Dec 2009

Study explains Salmonella's infection strategy

Salmonella are highly adaptive bacteria. They can live in the presence and absence of oxygen and thus propagate in the gut. The ingestion by humans occurs mainly via contaminated egg dishes such as mayonnaise or raw milk products as well as meat or sausages. Infections with Salmonella lead to severe diarrhea and fever, particularly in patients harbouring a compromised immune system.

17 Dec 2009

Next-generation DNA sequencing demonstrates potential in identifying mutations in SCLC

Applied Biosystems, part of Life Technologies Corporation, today announced the publication of a paper in the journal Nature that demonstrates the power of next-generation DNA sequencing used to identify DNA mutations in a small cell lung cancer (SCLC) line and identify the mutational burden associated with tobacco smoking.

17 Dec 2009

Cell News and Research

TSI organizes clinical, research and educational programs

Umbilical cord stem cells may be useful in treating blood disorders

New technology sheds light on intracellular transport

JDRF to work with Johnson & Johnson to develop drug targets and pathways for treating diabetes

Ambit Biosciences and Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

Flu-fighting proteins found in human cells stop flu virus, uncover scientists

Regulus Therapeutics wins exclusive rights to modulate microRNAs

Roche Diagnostics and Takara Bio enter into license agreement

Comprehensive approaches to understand the interaction of H1N1 strains with human cells

Phase 2 clinical study of STA-9090 in NSCLC initiated

ARIAD Pharmaceuticals completes enrollment of patients for Phase 3 clinical trial of ridaforolimus

Calorie-intake restriction can benefit longevity and help prevent cancer

Ligand Pharmaceuticals, Neurogen revise merger agreement

Scientists discover new model to asses homeostatic relationships between body substances

La Jolla Institute for Allergy & Immunology awarded $18.8M NIH grant for infectious diseases study

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

Promising breakthrough in adjuvant development may lead to cost-effective therapeutic vaccines

Study explains Salmonella's infection strategy

Next-generation DNA sequencing demonstrates potential in identifying mutations in SCLC

Improve fermentation and cell culture performance with real-time gas analysis eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo